



E-ISSN: 2321-2187
P-ISSN: 2394-0514
IJHM 2017; 5(2): 11-15
Received: 03-01-2017
Accepted: 04-02-2017

Andréia Pequeno
Department of Anatomy,
Universidad Nacional de Costa
Rica, Heredia, Costa Rica

Yendry Miranda
Department of Phytochemistry,
Universidad Nacional de Costa
Rica, Heredia, Costa Rica.

Gerardo Rodríguez
Department of Phytochemistry,
Universidad Nacional de Costa
Rica, Heredia, Costa Rica.

Víctor Valverde
Department of Phytochemistry,
Universidad Nacional de Costa
Rica, Heredia, Costa Rica

Luis Álvarez
Herbarium Juvenal Valerio
Rodríguez, Universidad Nacional
de Costa Rica, Heredia, Costa
Rica

Tania Da Silva
Department of Bioprospecting
Phytochemistry, Universidade
Federal Rural de Pernambuco,
Recife, Brazil

Valdemiro Da Silva Junior
Department of Animal
Morphology and Physiology,
Universidade Federal Rural de
Pernambuco, Brazil

Correspondence
Andréia Pequeno
Department of Anatomy,
Universidad Nacional de Costa
Rica, Heredia, Costa Rica

The genus *Witheringia*: A review of its traditional uses, phytochemistry and pharmacology

Andréia Pequeno, Yendry Miranda, Gerardo Rodríguez, Víctor Valverde, Luis Álvarez, Tania Da Silva and Valdemiro Da Silva Junior

Abstract

The genus *Witheringia* belongs to Solanaceae family. Some of its species are widely used in traditional medicine to cure several disorders such as diabetes, cancer, malaria, helminthic infections, inflammatory disorders, digestive problems and others manifestations like fever, skin disease and general pain. The phytochemistry of this genus has been poorly studied, however some researchers reported the presence of some phytoconstituents which includes alkaloids, saponins, tannins, flavonoids, anthraquinones and different types of withanolides such as physalins B, D and F. The physalins have attracted much attention in recent years due to their various biological activities. Despite the few studies, this plant has a promising pharmacological value for its various biological activities namely, anti-inflammatory, immunomodulatory, antimalarial and antidiabetic activities which are reported in the extracts of leaves and its phyto compounds of this plant. An overview of the current knowledge of the ethnopharmacology and phytochemical of the genus *Witheringia* and its physalins compounds is presented in this review.

Keywords: *Witheringia*, traditional herb, physalins, biological activities

1. Introduction

Medicinal herbs are a potential source of therapeutics aids and have attained a significant role in health systems all over the world, for both humans and animals, not only for treating diseases but also to prevent them^[1, 2].

Throughout the history of mankind, the importance of natural products for medicine and health has been enormous. Our ancestors used certain herbs to relieve pain, heal wounds and treat diseases. However, the advent of molecular biology and combinatorial chemistry has made possible the rational design of chemical compounds to target specific molecules^[2]. Thus, there has been an increase in interest in the use of natural compounds and, more importantly, their role as a basis for drug development^[3]. The modern tools of chemistry and biology now allow scientists to detail the exact nature of the biological effects of natural compounds on the human body, as well as to uncover possible synergies, which hold much promise for the development of new therapies against many devastating diseases^[2].

Herbal medicines and their extracts are a huge source of bioactive compounds, including primary and secondary metabolites^[4-9] such as physalins^[10]. Many plants belonging to the Solanaceae family contain physalins as major component. This compound has a wide range of ethnopharmacological applications. Physalins have attracted considerable attention because of their biological activities, and pharmacological investigations of these compounds have provided scientific support for the traditional uses of many physalins-producing plants^[10, 11].

These natural bioactive compounds play a central role in combating many human diseases and can be directly used as healing agent and their phytochemicals also serve as lead compound for developing potential drugs to cure various diseases in humans^[2, 3], yielding promising leads to further strengthen the medicinal system^[1].

Despite all these benefits of medicinal plants, little is known about the phytochemical constitution of genus *Witheringia* although some of its species are widely used in folk medicine^[12, 13]. In order to provide a better understanding of this genus and its benefits to human health, this review summarizes and discusses their description and distribution, traditional uses, phytochemical constituents with a special attention for physalins compounds and its pharmacological activities.

2. Botanical description and distribution

Plants of *Witheringia* are mostly tropical herbs and shrubs, distributed from Mexico to Bolivia, usually found growing between sea level and 2200 m, but with a concentration of species in Central America, especially in Costa Rica and Panama.

In Costa Rica, it is usually found on Rich soils of the Pacific slope from sea level to 1500 m [14]. Among all species of *Witheringia*, *Witheringia Solanaceae* is also the most widespread, with an ample geographic distribution from southern Mexico to southern Bolivia and several Caribbean islands and an altitudinal range from 0–1900 m [15]. It belongs to nightshade family, and resembles a tomato plant. It has the appearance of a short weak shrub with leaves paired with dense soft hairs; flowers pale yellow with green spots in basal half; fruit bright red, round, 7-12 mm. Flowers and fruits are present most of year, but more abundant in wet season [16-18].

3. Phytochemical constituents and physalins compounds

Physalins are the steroidal lactone constituents that often occur in Solanaceae family and have a variety of biological activities because of their complicated structures [19-22]. So far it is known a wide variety of physalins ranging from physalin A, discovered in 1965, to physalin Z. Besides, there have also been identified 4,7-didehydroneophysalin B, isophysalin B, 25,27-dihydro-4,7-dihehydro-7-deoxyneophysalin A, physalins I and II [23-31] and new discoveries of physalins continue to be reported [10, 32, 33].

The physalins containing an unique 13, 14-seco-16, 24-cycloergostane skeleton and are characterized by a highly oxygenated, complex, fused-ring system [22, 34, 35]. Based on the structural skeleton, physalins can be divided into two basic types: the physalin skeleton type with a keto carbonyl

group at C-15 along with an oxygen bridge at C-14/C-17 and the neophysalin skeleton type with a lactone carbonyl group at C-15 along with a carbon-carbon bond between C-14 and C-16. Neophysalin skeleton is considered a derived from physalin skeleton by the reaction of benzylic acid rearrangement [36]. All the known neophysalins have been isolated exclusively from *P. alkekengi* var. *Franchetii* [33]. A wide variety of physalins are differentiated by the number and position of the carbon-carbon double bond and substituent groups in the skeleton [10].

The phytochemistry of *Witheringia* genus is not well known. The chemical study is related for only three species: *Witheringia coccoloboides*, *W. hunziker* and *W. Solanaceae*. For *W. Solanaceae* some studies reported the presence of alkaloids, saponnins, tannins, flavonoids, anthraquinones and physalins [13]. The three species studied chemically have in common the presence of physalins. The physalin B (1) was isolated from three species [12, 37, 38], 25, 26-epidihydrophysalin C (2), physalin C (3), tetrahydrophysalin C (4), tetrahydrophysalin A (5) and epitetrahydrophysalin A (6) were found in *W. coccoloboides* [37]. Physalin D (7) was isolated from *W. Coccoloboides* [37] and *W. Solanaceae*. Physalin F (8) was showed only in the *W. Solanaceae* specie [12]. The Figure 1 show the physalins isolated from *Witheringia coccoloboides*, *W. hunziker* and *W. Solanaceae* species.




Fig 1: Physalins isolated from *Witheringia coccoloboides*, *W. hunziker* and *W. Solanaceae* species.

4. Traditional uses

In Latin American countries the *Whiteringia* genus is used as anti-inflammatory, antimicrobial agent, anti-hypertensive and for management of general pain and gastrointestinal disorders [11]. In Ecuadorian traditional medicine, these plants are extensively employed to treat a wide variety of diseases and symptoms such as allergies, skin diseases, helminthic infections, digestive disorders, illness of the respiratory system, disease of the urogenital system and disorders of the sensory system [18]. In Mexico, *Witheringia* is used in the treatment of anemia, fungal infections and acne [11]. In Costa Rican traditional medicine is employed as an antidiabetic agent [13].

5. Pharmacological activities

Witheringia genus has been used in various countries in popular medicines as a treatment for several illnesses as an anti-inflammatory, antimicrobial, anti-hypertensive agent. Therefore, these plants have attracted considerable attention because of their biological activities, and pharmacological investigations have provided scientific support for its traditional uses [12, 13, 39, 40].

In this section, we provide a concise summary of the biological and pharmacological activities scientifically proven on the *Witheringia* genus.

5.1 Anti-leishmanial activity

Leishmaniasis is an endemic disease in 98 countries and territories, with 1.2 million new cases per year, making it a worldwide concern [41]. It is an important human disease, very difficult to treat. During the last 50 years the best treatment has been the application of compounds based on pentavalent antimony derivatives; however, protozoal resistance is very frequent and long treatment is required. For this reason, many researchers around the world have been looking for anti-leishmanial chemical components present in several plant species and found in many parts of the *W. Solanaceae* a notorious antileishmanial activity. Also other studies demonstrated that physalins such as, physalin F; 6, 7-dehydrophysalin H; 6-deoxyphysalin H and isophysalin B have a significant anti-leishmanial activity [42-46].

5.2 Antimalarial activity

Despite substantial scientific progress over the past two decades, malaria remains a worldwide burden that causes hundreds of thousands of deaths every year [47]. New, affordable and safe drugs are required to overcome increasing resistance against artemisinin-based treatments, reinforcing the need for finding natural antimalarial components that would be found in plants [40, 47]. Just as their anti-leishmanial effect, this genus plant also has excellent antimalarial activity. Besides, many studies had proved that physalins B, D, F, and G have a potential antimalarial activity [40].

5.3 Anti-inflammatory activity

Jacobo-Herrera and collaborators, 2006, have demonstrated the pharmacological potential of physalins, especially, physalins B and F which were isolated from extracts of *Witheringia Solanaceae* leaves, which showed inhibitory activities on PMA-induced NFκB activation. They suggested that the presence of a double bond and an epoxy ring between carbons 5 and 6 in Physalins B and F, respectively, are related to their anti-inflammatory activity. Other research demonstrated that physalin E may be a potent and topically effective anti-inflammatory agent useful to treat the acute and chronic skin inflammatory conditions [48]. In addition Herrera

et al., demonstrated an anti-inflammatory effect of aqueous leaf extract from *W. Solanaceae* via systemic administration [39].

5.4 Antitumor activity

The Solanaceae family has a relevant antitumor activity, especially for the presence of physalins [49-54]. Regards *Whiteringia* genus, *W. coccoloboides* have demonstrated potential antitumor agents. The extract of *W. coccoloboides* roots presents two cytotoxic compounds, physalin B and 25, 26-epidihydrophysalin C [37, 38]. Both compounds have demonstrated cytotoxic activity in 9KB and 9PS tumor cells (*in vitro*). Additionally, physalin B has demonstrated moderate activity against the 3 PS mouse leukemia (cell) [36]. The physalins A and B are also found in *W. hunziker* which has an antitumor activity [37, 49].

5.5 Antidiabetic activity

Globally, the prevalence of chronic diseases is increasing at an alarming rate and diabetes is one of them [55]. Unlike currently available therapeutic options, there are a lot of herbal medicines that have been recommended for its treatment. Herbal medicines have long been used for the treatment of diabetes because they present no or few side effects [56-58]. Most of these plants have antioxidant activities and hence, prevent or treat hard curable diseases, other than having the property of combating the toxicity of toxic or other drugs [59, 60].

Regarding to *W. Solanaceae*, researches have demonstrated the hypoglycemic and anti-hyperglycemic potential of this herbal medicine in normal and alloxan induced hyperglycemic rats. These results suggest the presence of antidiabetic active principles in the *W. Solanaceae* leaves. However, further work is necessary to fractionate, purify and identify the bioactive principles present in the leaves of *W. Solanaceae* [13]. It is known that several plants containing physalins, especially *Physalis angulata* L. has antidiabetic effects [59, 61]. So, it is possible that the physalins present in *W. Solanaceae* have the same antidiabetic activity like *P. angulata* L.

6. Conclusion

This present review presents basic information on current knowledge for further studies about *Whiteringia* genus. Thus far it is known that in traditional medicine, these plants are widely used. However there are few and uncompleted studies that reveal its phytochemical constitution, even though it is already known that plants of the genus *Whiteringia* have important phytoconstituents as physalins which are endowed with a variety of biological activities. Thus, considering these biological and pharmacological activities and the identification of its bioactive compounds is possible provide solid scientific evidence for some of the traditional therapeutically claims. However further work is necessary to a better elucidation of its phytochemistry and to establish their therapeutic efficacy by *in vitro* and *in vivo* studies.

7. References

1. Verma S, Singh S. Current and future status of herbal medicines. *Vet World* 2008; 1:347-50.
2. Gilani AH, Rahman A. Trends in ethnopharmacology. *J Ethnopharmacol* 2005; 100:43-9.
3. Ji H-F, Li X-J, Zhang H-Y. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?

- EMBO Rep 2009; 10:194-200.
4. De la Torre L, Alarcón SD, Kvist PL, Salazar Lecaro J. Usos medicinales de las plantas. Encilopedia Las Plantas Útiles Del Ecuador 2008; 105-14.
 5. World Health Organization. WHO traditional medicine strategy 2014–2023. 2013. Geneva: World Health Organization. 2015.
 6. Agata K, Kusiak J, Stepien B, Bergier K, Kuźniak E. Bioaktywne metabolity wtórne roślin z rodzaju *Physalis* Bioactive secondary metabolites produced by plants of the genus *Physalis*. Postep Hig Med Dosw 2010; 64:665-73.
 7. Kamboj VP. Herbal medicine. Curr Sci 2000; 78:35-9.
 8. Mehta P, Shah R, Lohidasan S, Mahadikc KR. Pharmacokinetic profile of phyto constituent (s) isolated from medicinal plants-A comprehensive review. J Tradit Complement Med 2015; 5:207-27.
 9. Malla B, Gauchan DP, Chhetri RB. An ethnobotanical study of medicinal plants used by ethnic people in Parbat district of western Nepal. J Ethnopharmacol 2015; 165:103-17.
 10. Huang C, Xu Q, Chen C, Song C, Xu Y, Xiang Y, *et al.* The rapid discovery and identification of physalins in the calyx of *Physalis alkekengi* L. var. *franchetii* (Mast.) Makino using ultra-high performance liquid chromatography–quadrupole time of flight tandem mass spectrometry together with a novel three-step d. J Chromatogr a 2014; 1361:139-52.
 11. Mahalakshmi AM, Nidayani RB. *Physalis angulata* L: an ethanopharmacological review. Indo Am J Pharm Res 2014; 4:1479-86.
 12. Jacobo-Herrera NJ, Bremner P, Marquez N, Gupta MP, Gibbons S, Muñoz E, *et al.* Physalins from *Witheringia solanacea* as modulators of the NF-kappaB cascade. J Nat Prod 2006; 69:328-31.
 13. Herrera C, García-Barrantes PM, Binns F, Vargas M, Poveda L, Badilla S. *et al.* Hypoglycemic and antihyperglycemic effect of *Witheringia solanacea* in normal and alloxan-induced hyperglycemic rats. J Ethnopharmacol 2011; 133:907-10.
 14. Stone JL, Sasuclark MA, Blomberg CP. Variation in the self-incompatibility response within and among populations of the tropical shrub *Witheringia solanacea* (Solanaceae). Am J Bot. 2006; 93:592-8.
 15. Sousa-Pena M. Systematics and reproductive biology of the genus *Witheringia* l'Her. (Solanaceae). University of Connecticut. 2001.
 16. Doyle S. Predicted *Witheringia solanacea* Habitat in Costa Rica. Atlas of Maine. 2012; 2012.
 17. Haber WA. Monteverde Plants: *Witheringia solanacea*. Umass Bost. 2001.
 18. Caballero-George C, Vanderheyden PM, Solis PN, Pieters L, Shahat AA, Gupta MP, *et al.* Biological screening of selected medicinal Panamanian plants by radioligand-binding techniques. Phytomedicine 2001; 8:59-70.
 19. Soares MBP, Bellintani MC, Ribeiro IM, Tomassini TCB, Ribeiro dos Santos R. Inhibition of macrophage activation and lipopolysaccharide-induced death by seco-steroids purified from *Physalis angulata* L. Eur J Pharmacol. 2003; 459:107-12.
 20. Soares MBP, Brustolim D, Santos La, Bellintani MC, Paiva FP, Ribeiro YM, *et al.* Physalins B, F and G, seco-steroids purified from *Physalis angulata* L., inhibit lymphocyte function and allogeneic transplant rejection. Int Immunopharmacol 2006; 6:408-14.
 21. Makino B, Kawai M, Iwata Y, Yamamura H, Butsugan Y, Ogawa K, *et al.* Physalins Possessing an Endoperoxy Structure from *Physalis alkekengi* var. *franchetii*. Structural Revision of Physalin K. Bull Chem Soc Jpn 1995; 68:219-26.
 22. Yang B-Y, Xia Y-G, Pan J, Liu Y, Wang Q-H, Kuang H-X. *et al.* Phytochemistry and biosynthesis of δ -lactone withanolides. Phytochem Rev. 2015, 1-27.
 23. Kawai M, Yamamoto T, Makino B, Yamamura H, Araki S, Butsugan Y, *et al.* The structure of physalin T from *Physalis alkekengi* var. *franchetii*. J Asian Nat Prod Res. 2001; 3:199-205.
 24. Kawai M, Matsumoto A, Makino B, Mori H, Ogura T, Butsugan Y, *et al.* The Structure of Physalin P, a Neophysalin from *Physalis alkekengi*. Bull Chem Soc Jpn. 1993; 66:1299-300.
 25. Kawai M, Ogura T, Nakanishi M, Matsuura T, Butsugan Y, Mori Y, *et al.* Structure of physalin M isolated from *Physalis alkekengi* var. *franchetii*. Bull Chem Soc Jpn 1988; 61:2696-8.
 26. Kawai M, Ogura T, Makino B, Matsumoto A, Yamamura H, Butsugan Y, *et al.* Physalins N and O from *Physalis alkekengi*. Phytochemistry. 1992; 31:4299-302.
 27. Kawai M, Matsuura T, Kyuno S, Matsuki H, Takenaka M, Katsuoka T, *et al.* A New physalin from *Physalis alkekengi*: structure of physalin L. Phytochemistry. 1987; 26:3313-7.
 28. Row LR, Reddy KS, Sarma NS, Matsuura T, Nakashima R. New physalins from *Physalis angulata* and *Physalis lancifolia*. Structure and reactions of physalins D, I, G and K. Phytochemistry 1980; 19:1175-81.
 29. Kawai M, Matsuura T. The structure of physalin C: A bitter principle of *Physalis Alkekengi* var. *Franchetii*. Tetrahedron. 1970; 26:1743-5.
 30. Matsuura T, Kawai M. Bitter principles of *Physalis alkekengi* var. *Franchetii*: structure of physalin B. Tetrahedron Lett 1969; 10:1765-6.
 31. Matsuura T, Kawai M, Nakashima R, Butsugan Y. Bitter principles of *Physalis alkekengi* var. *Franchetii*: structure of physalin A. Tetrahedron Lett 1969; 10:1083-6.
 32. Xu X-M, Guan Y-Z, Shan S-M, Luo J-G, Kong L-Y. Withaphysalin-type withanolides from *Physalis minima*. Phytochem Lett 2016; 15:1-6.
 33. Li X, Zhao J, Yang M, Liu Y, Li Z, Li R, *et al.* Physalins and withanolides from the fruits of *Physalis alkekengi* L. var. *franchetii* (Mast.) Makino and the inhibitory activities against human tumor cells. Phytochem Lett 2014; 10:95-100.
 34. Makino B, Kawai M, Kito K, Yamamura H, Butsugan Y. New physalins possessing an additional carbon-carbon bond from *Physalis alkekengi* var. *franchetii*. Tetrahedron 1995; 51:12529-38.
 35. Zheng Y, Luan L, Chen Y, Ren Y, Wu Y. Characterization of physalins and fingerprint analysis for the quality evaluation of *Physalis alkekengi* L. var. *franchetii* by ultra-performance liquid chromatography combined with diode array detection and electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 2012; 71:54-62.
 36. Sunayama R, Kuroyanagi M, Umehara K, Ueno A. Physalin and neophysalins from *Physalis alkekengi* var. *franchetii* and their differentiation inducing activity. Phytochemistry 1993; 34:529-33.
 37. Antoun MD, Abramson D, Tyson RL, Chang CJ, McLaughlin JL, Peck G, *et al.* Potential antitumor agents. XVII. physalin B and 25,26-epidihydrophysalin C from

- Witheringia coccoloboides*. J Nat Prod. 1981; 44:579-85.
38. Karikas GA, Gupta MP, Ravelo AG, Gonzales AG. Physalin B from *Witheringia huziker*. Fitoterapia 1998; 69:468-9.
 39. Herrera C, Durán O, Binns F. Actividad antiinflamatoria de un extracto acuoso de las hojas de *Witheringia solanacea*. XXII Congr. Italo-Latinoamericano Etnomedicina, Puntarenas, Costa Rica: 2013, 355-6.
 40. Chinchilla M, Valerio I, Sánchez R, Mora V, Bagnarello V, Martínez L, et al. *In vitro* antimalarial activity of extracts of some plants from a biological reserve in Costa Rica. Rev Biol Trop. 2012; 60:881-91.
 41. Chinchilla Carmona M, Valerio Campos I, Sánchez Porras R, Bagnarello Madrigal V, Martínez Esquivel L, González Paniagua A, et al. Anti-leishmanial activity in plants from a Biological Reserve of Costa Rica. Rev Biol Trop. 2014; 62:1229-40.
 42. Guimarães ET, Lima MS, Santos LA, Ribeiro IM, Tomassini TBC, Ribeiro dos Santos R, et al. Activity of physalins purified from *Physalis angulata* in *in vitro* and *in vivo* models of cutaneous leishmaniasis. J Antimicrob Chemother. 2009; 64:84-7.
 43. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. J Am Acad Dermatol 2015; 73:897-908.
 44. Choudhary MI, Yousuf S, Shah SAA, Ahmed S. Biotransformation of Physalin H and Leishmanicidal Activity of Its Transformed Products. Chem Pharm Bull (Tokyo) 2006; 54:927-30.
 45. Nogueira RC, Rocha VPC, Nonato FR, Tomassini TCB, Ribeiro IM, dos Santos RR, et al. Genotoxicity and antileishmanial activity evaluation of *Physalis angulata* concentrated ethanolic extract. Environ Toxicol Pharmacol. 2013; 36:1304-11.
 46. Raick R, Silva P, Silva BJM, Rodrigues APD, Farias LHS, Silva MN, et al. *In vitro* biological action of aqueous extract from roots of *Physalis angulata* against *Leishmania (Leishmania) amazonensis*. BMC Complement Altern Med 2015, 1-10.
 47. Wells TNC, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov 2015; 14:424-42.
 48. Pinto NB, Morais TC, Carvalho KMB, Silva CR, Andrade GM, Brito GAC, et al. Topical anti-inflammatory potential of Physalin E from *Physalis angulata* on experimental dermatitis in mice. Phytomedicine 2010; 17:740-3.
 49. Karikas G a. Anticancer and chemopreventing natural products: Some biochemical and therapeutic aspects. J BUON. 2010; 15:627-38.
 50. Magalhães HIF. Atividade antitumoral (*In vitro e in vivo*) das fisalinas de *Physalis angulata* lin. Universidade Federal do Ceará. 2005.
 51. Magalhães HIF, Veras ML, Torres MR, Alves APNN, Pessoa ODL, Silveira ER, et al. In-vitro and in-vivo antitumour activity of physalins B and D from *Physalis angulata*. J Pharm Pharmacol. 2006; 58:235-41.
 52. Ma Y, Han W, Li J, Hu L, Zhou Y. Physalin B not only inhibits the ubiquitin-proteasome pathway but also induces incomplete autophagic response in human colon cancer cells *in vitro*. Acta Pharmacol Sin. 2015; 36:517-27.
 53. Han H, Qiu L, Wang X, Qiu F, Wong Y, Yao X. et al. Physalins A and B inhibit androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression. Biol Pharm Bull 2011; 34:1584-8.
 54. Ooi KL, Tengku Muhammad TS, Sulaiman SF. Physalin F. from *Physalis minima* L. triggers apoptosis-based cytotoxic mechanism in T-47D cells through the activation caspase-3- and c-myc-dependent pathways. J Ethnopharmacol 2013; 150:382-8.
 55. Haque N, Salma U, Nurunnabi TR, Uddin MJ, Jahangir MFK, Islam SMZ, et al. Management of type 2 diabetes mellitus by lifestyle, diet and medicinal plants. Pakistan J Biol Sci PJBS. 2011; 14:13-24.
 56. Sanchooli N. Antidiabetic Properties of *Physalis alkekengi* Extract in Alloxan-Induced Diabetic Rats. Res J Pharm Biol Chem Sci 2011; 2:168-73.
 57. Hassan AI, Ghoneim M, M. A possible inhibitory Effect of *physalis (physalis pubescens L.)* on diabetes in male rats. World Appl Sci J 2013; 21:681-8.
 58. Raju P, Mamidala E. Anti-diabetic activity of compound isolated from *Physalis angulata* fruit extracts in alloxan induced diabetic rats. Am J Sci Med Res 2015; 1:40-3.
 59. Sateesh Poojari RP, EM. Phytochemical Analysis and *In Vitro* Antidiabetic Activities of *Physalis Angulata* Fruit Extracts. Natl J Integr Res Med 2014; 5:34-8.
 60. El-mehiry HF, Helmy HM, El-ghany MAA. Antidiabetic and Antioxidative Activity of *Physalis* Powder or Extract with Chromium in Rats. World J Med Sci 2012; 7:27-33.
 61. Poojari S, Mamidala E. Anti-diabetic activity of Physagulin-F isolated from *Physalis angulata* fruits. Am J Sci Med Res. 2015; 1:53-60.